• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo
- - - - -

Diprovocim synergizes with anti–PD-L1 to eliminate melanoma in mice

melanoma senescent cells

  • Please log in to reply
2 replies to this topic
⌛⇒ write a quiz!

#1 stefan_001

  • Guest
  • 928 posts
  • 161
  • Location:Munich

Posted 12 September 2018 - 09:50 AM


http://www.pnas.org/...809232115.short

Immunization against a genetically engineered tumor-specific antigen, ovalbumin, when adjuvanted with Diprovocim, inhibited growth of B16 melanoma and prolonged survival in the presence of immune checkpoint blockade by anti–PD-L1; 100% of mice responded to treatment. Our data suggest Diprovocim boosts the success of anti–PD-L1 treatment by increasing the number and activation of tumor-specific CTLs capable of responding to this checkpoint inhibitor.

 

This sounds like good news for Melanoma, these are existing compounds

 

I found this portion interesting:

We report the immunological effects of the synthetic chemical adjuvant Diprovocim, which targets the innate immune receptor TLR1/TLR2 in mice and humans.

 

Some research indicates that TLR2 is upregulated in senescene process, so perhaps combing senolytics with Diprovocim would increase effectiveness.



#2 joelcairo

  • Guest
  • 495 posts
  • 132
  • Location:Calgary, Alberta, Canada
  • NO

Posted 12 September 2018 - 06:38 PM

I don't know about the theory, but I can find virtually no reference to Diprovocim anywhere except in relation to this study. It was developed just last year by the same team that published this melanoma study. I assume it will take years to come to market (if ever) and will be very expensive.



sponsored ad

  • Advert
Click HERE to rent this advertising spot for SUPPLEMENTS (in thread) to support LongeCity (this will replace the google ad above).

#3 stefan_001

  • Topic Starter
  • Guest
  • 928 posts
  • 161
  • Location:Munich

Posted 12 September 2018 - 08:21 PM

Found the filing. Its by Scripps:

https://patents.goog...2018005812A1/en

 

you are right this may take a long time to get to market. It is possible to buy it today however as research chemical, but risky. I guess I should do a search for other tlr agonists.

 


Edited by stefan_001, 12 September 2018 - 08:44 PM.






Also tagged with one or more of these keywords: melanoma, senescent cells

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users